eF­FEC­TOR's lead lung can­cer pro­gram falls through, stock crash­es

eF­FEC­TOR Ther­a­peu­tics won’t be mov­ing its lead can­di­date for­ward in front­line non-small cell lung can­cer af­ter its ex­per­i­men­tal drug failed a Phase 2 study. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER